Ironwood Pharmaceuticals vs Liquidia
Ironwood Pharmaceuticals is the larger business, with $296m of revenue in fiscal 2025 against $158m for Liquidia (1.9 times as much). Liquidia grew faster (1031.2% against -15.7%). Ironwood Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 8.1% against -43.5%.
| Latest fiscal year | Ironwood PharmaceuticalsIRWD, 2025 | LiquidiaLQDA, 2025 |
|---|---|---|
| Revenue | $296m | $158m |
| Revenue growth | -15.7% | 1031.2% |
| Net income | $24.0m | −$68.9m |
| Operating margin | 33.3% | -32.5% |
| Net margin | 8.1% | -43.5% |
| Return on equity | — | -111.1% |
| Free cash flow | $127m | −$40.0m |
| Cash | $215m | $191m |
| Total debt | $585m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 100 | 216 |
| Market value | $582m | $3.72bn |
| Price vs our value range | Below our value range | — |
| Moat score | 31 (Weak) | 20 (Weak) |
| Insider trades, 12 months | 0 buys, 18 sales | 1 buys, 175 sales |